<tbody id="ff6si"><div id="ff6si"></div></tbody>
  • <track id="ff6si"></track>

    1. <option id="ff6si"></option>

    2. <option id="ff6si"></option>
      1. <track id="ff6si"></track>

          Fresenius Group Overview

          Outlook

          Group Outlook 2019

          In 2019, we expect to increase Group sales1 by 3% to 6% in constant currency. We project Group net income2,3 to increase by ~ 0% in constant currency.

            Targets 2019 Fiscal year 20184
          Fresenius Group
          Sales growth (in constant currency) 3% – 6%5 € 33,009 million

          Net income2 growth
          (in constant currency)

          ~0%6 € 1,872 million
          Fresenius Medical Care

          Sales growth (in constant currency)

          3% – 7%6 € 16,026 million
          Net income7 growth (in constant currency) -2% – +2%6 € 1,341 million
          Fresenius Kabi
          Sales growth (organic) 3% – 6%6 € 6,544 million
          EBIT growth (in constant currency) 3% – 6%6 € 1,139 million
          Fresenius Helios
          Sales growth (organic) 2% – 5%6 € 8,993 million
          EBIT growth -5% – -2%6 € 1,052 million
          Fresenius Vamed
          Sales growth (organic) ~10%6 € 1,688 million
          EBIT growth 15% – 20%6 € 110 million

           

          • 1 Base 2018: €33,009 million; 2018 adjusted for divestitures of Care Coordination activities at FMC (H1 / 18); 2019 adjusted for IFRS 16 effects, excluding effects from pending acquisition of NxStage by FMC
          • 2 Net income attributable to shareholders of Fresenius SE & Co. KGaA
          • 3 Base 2018: € 1,872 million; 2018 before special items and adjusted for divestitures of Care Coordination activities at FMC (H1 /18); 2019 before special items (before transaction-related expenses, expenses associated with the cost optimization program at FMC, revaluations of biosimilars contingent liabilities), adjusted for IFRS 16 effects, excluding effects from pending acquisition of NxStage by FMC
          • 4 Before special items and after adjustments
          • 5 Adjusted for effects of IFRS 16, excluding effects from pending acquisition of NxStage by FMC
          • 6 Before special items (before transaction-related expenses, expenses associated with the cost optimization program at FMC, revaluations of biosimilars contingent liabilities), adjusted for IFRS 16 effects, excluding effects from pending acquisition of NxStage by FMC
          • 7 Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA
          •  
          • As of December 31, 2018

           

          青草青青